Ertugliflozin for treatment of patients with Type 2 diabetes mellitus

References

• International Diabetes Federation. Diabetes atlas. Sixth edition. (cited 2018 Mar 15) Available from: http://www.idf.org/diabetesatlas.
   Google Scholar
• Centers for Disease Control and Prevention. Diabetes report card, 2012. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services. cited 2018 Mar 15. Available from: http://www.cdc.gov/diabetes/pubs/pdf/diabetesreportcard.pdf
   Google Scholar
• Ford ES. Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: findings from the National Health and Nutrition Examination Survey 1999–2008. J Diabetes. 2011;3(4):337–347.
   PubMed Web of Science ®Google Scholar
• Ghosh RK, Ghosh SM, Chawla S, et al. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52(4):457–463.
   PubMed Web of Science ®Google Scholar
• Verma S, Mazer CD, Al-Omran M, et al. Cardiovascular outcomes and safety of empagliflozin in patients with Type 2 diabetes mellitus and peripheral artery disease a subanalysis of empa-reg outcome[J]. Circulation. 2018 23;137(4):405–407.
   PubMed Web of Science ®Google Scholar
• Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: apotent, selective renal sodium dependent glucose co-transporter 2(SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51(5):1145–1149.
   PubMed Web of Science ®Google Scholar
• Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin(BMS-512148), a potent sodium-glucosecotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38(3):405–414.
   PubMed Web of Science ®Google Scholar
• Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem. 2010;53(17):6355–6360.
   PubMed Web of Science ®Google Scholar
• Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2,dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13(7):669–672.
   PubMed Web of Science ®Google Scholar
• Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes ObesMetab. 2012;14(1):83–90.
   PubMed Web of Science ®Google Scholar
• Luippold G, Klein T, Mark M, et al. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab. 2012;14(7):601–607.
   PubMed Web of Science ®Google Scholar
• Singh M, Kumar A. Risks associated with SGLT2 inhibitors: an overview. Curr Drug Saf. 2018;13(2):84–91.
   Web of Science ®Google Scholar
• Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation. 2016;134(10):752–772.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev. 2011;27(6):528–542.
   PubMed Web of Science ®Google Scholar
• Rizzi M, Trevisan R. Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors. Nutr Metab Cardiovasc Dis. 2016;26(11):963–970.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium glucosecotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232–1238.
   PubMed Web of Science ®Google Scholar
• Jf Y, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463–473.
   PubMed Web of Science ®Google Scholar
• Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–1380.
   PubMed Web of Science ®Google Scholar
• Li D, Yang JY, Wang T, et al. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials[J]. Diabetes Metab. 2018;S1262–3636(18):30041–30047.
   Google Scholar
• Dash RP, Babu RJ, Srinivas NR. Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview. Xenobiotica. 2017 Nov;47(11):1015–1026.
   PubMed Web of Science ®Google Scholar
• FDA. STEGLATRO™ (ertugliflozin) tablets, for oral use. (cited 2017 Dec 19) Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803Orig1s000lbl.pdf.
   Google Scholar
• Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013;41(2):445–456.
   PubMed Web of Science ®Google Scholar
• Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–142.
   PubMed Web of Science ®Google Scholar
• Jiang M, Steyger PS. An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus. Expert Opin Ther Pat. 2015;25(11):1349–1352.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5–14.
   PubMed Web of Science ®Google Scholar
• Lu Y, Griffen SC, Boulton DW, et al. Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. Front Pharmacol. 2014;5:274.
   PubMed Web of Science ®Google Scholar
• Wang XX, Levi J, Luo Y, et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation and the development of nephropathy in diabetic mice. J Biol Chem. 2017;292(13):5335–5348.
   PubMed Web of Science ®Google Scholar
• Solini A, Rossi C, Mazzanti CM, et al. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(9):1289–1294.
   PubMed Web of Science ®Google Scholar
• Amin NB, Wang X, Mitchell JR, et al. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17(8):805–808.
   PubMed Web of Science ®Google Scholar
• Markham A. Ertugliflozin: first global approval. Drugs. 2018;78(4):513–519.
   Google Scholar
• Kalgutkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011;39(9):1609–1619.
   PubMed Web of Science ®Google Scholar
• Sahasrabudhe V, Terra SG, Hickman A, et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with Type 2 diabetes mellitus[J]. J Clin Pharmacol. 2017;57(11):1432–1443.
   PubMed Web of Science ®Google Scholar
• Amin NB, Wang X, Jain SM, et al. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17(6):591–598.
   PubMed Web of Science ®Google Scholar
• Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetesmellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721–728.
   PubMed Web of Science ®Google Scholar
• Aronson R, Frias J, Goldman A, et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: vERTISMONO extension study. Diabetes Obes Metab. 2018;20(6):1453–1460.
   Web of Science ®Google Scholar
• Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, bodyweight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTISMET). Diabetes Obes Metab. 2018;20(3):520–529.
   PubMed Web of Science ®Google Scholar
• Hollander P, Liu J, Hill J, et al. Ertugliflozin compared with glimepiride in patients with Type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther. 2018;9(1):193–207.
   PubMed Web of Science ®Google Scholar
• Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with Type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther. 2018;9(1):253–268.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTISFACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111–1120.
   Google Scholar
• Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTISSITA 2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530–540.
   PubMed Web of Science ®Google Scholar
• Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and Type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9(1):49–66.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Cardiovascular outcomes following ertugliflozin treatment in Type 2 diabetes mellitus participants with vascular disease, the VERTIS CV study (MK-8835-004) (cited 2018 Jun 14) Available from: https://clinicaltrials.gov/ct2/show/NCT01986881?term=ertugliflozin&rank=4
   Google Scholar
• Sahasrabudhe V, Saur D, Matschke K, et al. A phase 1,randomized,placebo-andactive-controlled crossover study to determine the effect of single-dose ertugliflozin on QTc interval in healthy volunteers. Clin Pharmacol Drug Dev. 2018;7(5):513–523.
   Web of Science ®Google Scholar
• Defronzo RA. Banting Lecture. From the triumvi rate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379.
   PubMed Web of Science ®Google Scholar
• Ghosh RK, Ghosh SM, Chawla S, et al. inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52:457–463.
   PubMed Web of Science ®Google Scholar
• Upadhyay J, Polyzos SA, Perakakis N, et al. Pharmacotherapy of type 2 diabetes: an update. Metabolism[J]. 2018;78:13–42.
   Google Scholar
• Katsiki N, Mikhailidis DP, Theodorakis MJ, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management [J]. Curr Pharm Des. 2017;23(10):1522–1532.
   PubMed Web of Science ®Google Scholar